Ask the Experts
Meet our Expert: Dr. Stuart McDougall
Learn more about Stuart's areas of expertise and ask a question.
Dr. Stuart McDougall: Vice President of BioAnalysis
Stuart McDougall is the Vice President of Bioanalysis at Quotient Sciences. Stuart has over 30 years of experience in the pharmaceutical industry within Metabolism, Pharmacokinetic and Bioanalysis roles.
Previous relevant positions include the global leader of Sanofi-Aventis bioanalytical strategy team and a member of Covance global bioanalytical leadership team.
Stuart is a pharmacology graduate from the University of Dundee, a harmonization team leader for the Global Bioanalytical Consortium (GBC), represents Quotient on the European Bioanalytical Forum (EBF) and is an author and co-author of numerous scientific papers.
Connect on LinkedIn
Ask a question
If you have a question for Dr. Stuart McDougall, fill out the form below.
Learn more
-
WebinarStreamlining the Delivery of 14C Human ADME Data: An ADME Q&A RoundtableOn December 6, 2022, join Quotient Sciences and The Netherlands Organization for Applied Scientific Research (TNO) for an interactive, hour-long live Q&A webinar focused on streamlining human ADME studies.
-
Scientific PostersAAPS 2022 Poster: Kilo Scale Synthesis in Daisy Chained Flow ReactorsQuotient Sciences AAPS 2022 Poster, "Kilo Scale Synthesis in Daisy Chained Flow Reactors." (2R, 6R) hydroxynorketamine is a pharmaceutical undergoing trials as an antidepressant. An atom efficient synthesis route with norketamine as an intermediate is known. A low throughput flow synthesis route to norketamine had previously been developed, 2 however a manufacturing scale method was required. The objective of this study is to conduct the entire synthesis of norketamine from 2 chlorophenylcyclopentyl ketone in daisy chained reactors, built mainly from readily available parts at a throughput of > 1 kg/day.
-
Scientific PostersAAPS 2022 Poster: Formulation and Taste Assessments in First in Human StudiesQuotient Sciences AAPS 2022 Poster, "Formulation and Taste Assessments in First in Human Studies"
-
Info SheetQuotient Sciences Aseptic Development & Manufacturing Capabilities Info SheetQuotient Sciences has expertise in developing, manufacturing, testing, releasing, and supplying a range of formulations (IV, SC, and IM administration) for a variety of clinical study types, including first-in-human (FIH) healthy volunteer studies assessing safety, tolerability, and pharmacokinetics (PK), as well as radiolabeled formulations for human absorption, distribution, metabolism, and excretion (ADME) studies.